MedeliX
Start asking

Captopril

Kapril, Kaptoril, Nobepril · ATC code C09AA01

Also known as: Kaptopril · Brand names: Captopril Abz, Captopril Al, Captopril Denk, Captopril Stada, Noyada, Kapril, Kaptoril, Nobepril

Key facts
Active substance
Captopril
Drug class
ACE inhibitor
ATC code
C09AA01
Authorisation
authorised nationally; no central EU authorisation
Information as of
2026-10-29

Boxed warning

  • When pregnancy is detected, discontinue captopril tablets as soon as possible.
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity

Key facts

Captopril is an ACE inhibitor. Per the US prescribing information, it is used for hypertension, heart failure, left ventricular dysfunction after myocardial infarction and diabetic nephropathy.

What it is used for

  • Hypertension, alone or in combination, especially with thiazide-type diuretics
  • Congestive heart failure, usually with diuretics and digitalis
  • Left ventricular dysfunction (ejection fraction up to 40%) after myocardial infarction in clinically stable patients, to improve survival
  • Diabetic nephropathy (proteinuria above 500 mg/day) in type I diabetes with retinopathy

Dosing

  • Take one hour before meals; individualize the dose
  • Hypertension: start with 25 mg b.i.d. or t.i.d.; after one or two weeks may increase to 50 mg b.i.d. or t.i.d.; usual range 25 to 150 mg b.i.d. or t.i.d.
  • Heart failure: usually 25 mg t.i.d.; in vigorously diuresed, hypovolemic patients start with 6.25 or 12.5 mg t.i.d.
  • After myocardial infarction: target maintenance dose 50 mg t.i.d.; diabetic nephropathy: 25 mg t.i.d.
  • Maximum daily dose 450 mg
  • Significant renal impairment: lower initial daily dose and smaller titration steps; see the full prescribing information

Contraindications

  • Hypersensitivity to captopril or any other ACE inhibitor (e.g. angioedema with another ACE inhibitor)
  • Co-administration with aliskiren in patients with diabetes
  • Combination with a neprilysin inhibitor (e.g. sacubitril); do not give within 36 hours of switching to or from sacubitril/valsartan

Important warnings

  • Boxed warning: fetal toxicity – drugs acting on the renin-angiotensin system can injure and kill the developing fetus; discontinue as soon as possible when pregnancy is detected
  • Head and neck angioedema with possibly fatal airway obstruction; increased risk with mTOR or neprilysin inhibitors; intestinal angioedema also possible
  • Neutropenia/agranulocytosis, with higher risk in renal impairment and collagen vascular disease
  • Hypotension, particularly in patients on diuretics or with salt/volume depletion
  • Hyperkalemia, particularly with renal insufficiency, diabetes mellitus or potassium-raising drugs

Side effects

  • Rash, often with pruritus, in about 4 to 7 of 100 patients, usually in the first four weeks
  • Proteinuria in about one of 100 patients
  • Pruritus without rash in about 2 of 100 patients; flushing or pallor
  • Hypotension
  • Neutropenia/agranulocytosis, anemia, thrombocytopenia, pancytopenia

Interactions

  • Aliskiren and other renin-angiotensin system blockers; neprilysin inhibitors
  • Diuretics: enhanced blood pressure fall at the start of therapy
  • Potassium-raising drugs: hyperkalemia
  • Lithium: increased lithium levels and toxicity reported; coadminister with caution
  • mTOR inhibitors (temsirolimus, sirolimus, everolimus): increased risk of angioedema

Pregnancy and breastfeeding

  • Discontinue as soon as possible when pregnancy is detected; can injure and kill the developing fetus

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Patient information (US)

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

Germany

  • Captopril AbzAbz-Pharma Gmbh · 1 register entry
  • Captopril AlAliud Pharma Gmbh · 1 register entry
  • Captopril DenkDenk Pharma Gmbh & Co. Kg · 1 register entry
  • Captopril StadaStadapharm Gmbh · 1 register entry
  • NoyadaEthypharm · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

  • KaprilGENSENTA İLAÇ SANAYİ VE TİC. A.Ş. · 1 register entry
  • KaptorilDEVA HOLDİNG A.Ş. · 4 register entries
  • NobeprilNOBEL İLAÇ SAN. VE TİC. A.Ş. · 4 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 23 more European countries
Belgium
Captopril Eg
Bulgaria
Каптоприл Софарма
Cyprus
Aceprotin, Bocapril, Epsitron, Hurmat
Czechia
Tensiomin
Denmark
Captopril Stada
Estonia
Kaptopril Krka
France
Captopril Arrow, Captopril Biogaran, Captopril Eg, Captopril Viatris, Captopril Zydus, Noyada
Greece
Normolose
Hungary
Aceomel, Tensiomin
Italy
Captopril Eg, Captopril Mylan Generics
Latvia
Kaptopril Krka
Lithuania
Kaptopril Krka
Luxembourg
Captopril Eg
Malta
Captopril Ac, Captopril Accord Healthcare, Captopril Sugar Free Thame, Rilcapton
Netherlands
Captopril Accord, Captopril Mylan
Norway
Captopril Viatris, Cuopril
Poland
Captopril Jelfa, Captopril Polfarmex
Portugal
Capritin, Captopril Bluepharma, Captopril Convertal, Captopril Farmoz, Captopril Generis, Captopril Gp, Captopril Mylan, Captopril Ratiopharm, Hipotensil
Romania
Captopril Ac, Captopril Arena, Captopril Laropharm, Captopril Lph Labormed, Captopril Mcc, Captopril Sintofarm, Captopril Terapia
Slovakia
Tensiomin
Slovenia
Kaptopril Krka
Spain
Captopril Alter, Captopril Cinfa, Captopril Normon
Sweden
Captopril Viatris

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Related calculators

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. U.S. Food and Drug Administration. captopril (AMICI PHARMA, INC.) – Prescribing Information, 2026-09-14. DailyMed (NLM), 2026-10-29. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1395ba5b-2fc9-41ff-9c43-e0740d781dee
  2. EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
  3. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  4. Wikidata (CC0): ATC C09AA.

Editorial: Medelix editorial team · last updated 2026-10-29 · How these pages are made · Report an error

Source: U.S. Food and Drug Administration (FDA), prescribing information, via DailyMed (NLM); public domain. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.